Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q15831

UPID:
STK11_HUMAN

ALTERNATIVE NAMES:
Liver kinase B1; Renal carcinoma antigen NY-REN-19

ALTERNATIVE UPACC:
Q15831; B2RBX7; E7EW76

BACKGROUND:
The protein Serine/threonine-protein kinase STK11, known alternatively as Liver kinase B1, is a tumor suppressor that orchestrates a wide array of cellular processes including metabolism, cell polarity, and the DNA damage response. It acts by phosphorylating AMPK family proteins, thereby regulating cell growth and proliferation, especially under energy stress conditions.

THERAPEUTIC SIGNIFICANCE:
Given STK11's critical role in Peutz-Jeghers syndrome and its association with testicular germ cell tumors, its study offers promising avenues for therapeutic intervention. Understanding the role of STK11 could open doors to potential therapeutic strategies, particularly in the context of these diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.